5 ASX Health stocks to add to your porfolio

Marc Kennis Marc Kennis, April 26, 2024

5 ASX Health Stocks

Stuart Roberts from Stocks Down Under discussed the potential promise of biotech, sharing his perspectives about the industry’s future amidst changing interest rates. He compares the current market situation to 1994 when the introduction of interest rate tightenings led to bear markets for many pre-revenue stocks. However, despite ongoing mildly bearish market conditions since 2022, Stuart discussed on many stocks rallying ahead of potential peaks in interest rates.

 

The next Neuren Pharmaceuticals

Speaking on breakthroughs in the sector, Neuren Pharmaceuticals (ASX:NEU) is highlighted by Stuart for its strong progress, particularly with its drug to treat Rett syndrome, a severe autism spectrum disorder, leading to a significant increase in its stock value. Other promising ASX Health stocks mentioned include Actinogen (ASX:ACW), whose developing drug could potentially slow down cognitive decline in depression and Alzheimer’s patients, and Recce Pharmaceuticals (ASX:REH) who are working on a solution for antimicrobial resistance, an increasingly pressing issue in healthcare.

Stuart then brings attention to a few potential rising stars in the sector like Biotron Limited (ASX:BIT), another company targeting diseases prevalent in the ageing population such as Alzheimer’s. He provides further insights into companies like Immutep Limited (ASX:IMM), and Opthea Limited (ASX:OPT), which are making strides in cancer and eye disease treatments respectively. Stuart says the sector’s ongoing potential while urging investors to undertake diligent research due to the inherent risk associated with biotech stocks.

 

WATCH THE ENTIRE INTERVIEW HERE

ASX Health stocks

 

 

What are the Best ASX Health Stocks to invest in right now?

Check our buy/sell tips

 

Blog Categories

Get Our Top 5 ASX Stocks for FY25

Recent Posts

Growth Stocks

8 Growth Stocks to Watch This Month — Will They Beat Market Uncertainty?

Mid-way through 2025, markets remain anything but predictable. As they continue to experience volatility, investors are constantly looking for opportunities…

Indo-Pacific Defence Tech stocks

Indo-Pacific Tensions Rise — Is Defence Tech the Next Sector to Surge?

As the geopolitical chessboard in the Indo-Pacific becomes increasingly volatile, markets are watching for signals of where capital might flow…

Adairs

Adairs (ASX: ADH): After copping a massive beating in 2022-23, shares are on their way back up

After shedding 75% between mid-2021 and mid-2023, Adairs (ASX: ADH) shares have been on a slow and steady recovery, more…